Professor of Neurology
Director, Cincinnati Epilepsy Center
Medical Education: State University of New York, Syracuse Health Science Center
Residency Training: Georgetown University Medical Center (Neurology)
Fellowship Training: University of Texas, Southwestern Medical Center (Epilepsy/EEG)
Board Certification: Neurology and Clinical Neurophysiology
Clinical Interests: New antiepileptic drugs, epilepsy surgery, video/EEG
Research Interests: Development of antiepileptic drugs, evaluation for epilepsy surgery
Selected Publications:
Please click here for the National Library of Medicine's link to Dr. Privitera's publications.
Privitera MD, Quinlan JG, Yeh HS. Interictal spike detection comparing subdural and depth electrodes. Electroenceph Clin Neurophysiol 1990;76:379-387.
Privitera MD, Morris GL, Gilliam F. Postictal language assessment and lateralization of complex partial seizures. Ann Neurol 1991;30:391-396.
Yeh HS, Privitera MD. Secondary epileptogenesis in cerebral arteriovenous malformations. Arch Neurol 1991;48:1122-1124.
Privitera MD. Clinical rules for phenytoin dosing. Annals of Pharmacotherapy 1993;27:1169-1173.
Privitera MD, Hoffman M, Moore JL, Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Research 1994;18:155-166.
Privitera MD, Treiman DM, Pledger GW, Sahlroot JT, Handforth A, Linde MS, France CR, Cereghino JJ, McCutchen CB, Wood JH. Dezinamide for partial seizures:Results of an n-of-1 design trial. Neurology 1994;44:1453-1458.
Privitera MD, Fincham R, Penry JK, Reife R, Kramer L, Pledger G, Karim R, and the Topiramate YE Study Group. Topiramate placebo-controlled, dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-1683.
Arnold L, Privitera MD. Psychopathology and trauma in epileptic and psychogenic seizure patients. Psychosomatics 1996;37:438-443.
Privitera MD, Kohler C, Cahill W, Yeh HS. Postictal language dysfunction in patients with right or bilateral hemispheric language localization. Epilepsia 1996;37:936-941.
Privitera MD, Fincham R, Penry JK, Reife R, Kramer L, Pledger G, Karim R, and the Topiramate YE Study Group. Topiramate placebo-controlled, dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-1683.
Arnold L, Privitera MD. Psychopathology and trauma in epileptic and psychogenic seizure patients. Psychosomatics 1996;37:438-443.
Arnold L, Privitera MD. Psychopathology and trauma in epileptic and psychogenic seizure patients (letter). Psychosomatics 1996;37:438-443.
Privitera MD. Topiramate:
A new antiepileptic drug. Ann
Pharmacother 1997;31:1164-1173.
Welty T, Privitera MD. Increased seizure frequency following felbamate discontinuation. Arch Neurology 1998;55:641-645.
Chadwick DE, Privitera MD. Placebo-controlled trials of antiepileptic drugs: Where do they stop? Neurology, 1999;52:682-685.
Privitera MD. The Progressive Nature of Epilepsy and Its Impact on Treatment Decisions August 19, 2000. Available at: http://www.medscape.com/medscape/Neurology/TreatmentUpdate/2000/tu06/public/toc-tu06.html
Privitera MD. Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials. Epilepsia, 2001;42:Suppl. 4.
"Topiramate" chapter in Wyllie E, The Treatment of Epilepsy Text, Lippincott, Williams & Wilkens, 3rd edition. 2001;64:939-946.